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Abstract
A variety of models have been proposed to explain regions of recurrent somatic copy num-
ber alteration (SCNA) in human cancer. Our study employs Whole Genome DNA Sequence
(WGS) data from tumor samples (n = 103) to comprehensively assess the role of the Knud-
son two hit genetic model in SCNA generation in prostate cancer. 64 recurrent regions of
loss and gain were detected, of which 28 were novel, including regions of loss with more
than 15% frequency at Chr4p15.2-p15.1 (15.53%), Chr6q27 (16.50%) and Chr18q12.3
(17.48%). Comprehensive mutation screens of genes, lincRNA encoding sequences, con-
trol regions and conserved domains within SCNAs demonstrated that a two-hit genetic
model was supported in only a minor proportion of recurrent SCNA losses examined (15/
40). We found that recurrent breakpoints and regions of inversion often occur within Knud-
son model SCNAs, leading to the identification of ZNF292 as a target gene for the deletion
at 6q14.3-q15 and NKX3.1 as a two-hit target at 8p21.3-p21.2. The importance of alterations
of lincRNA sequences was illustrated by the identification of a novel mutational hotspot at
the KCCAT42, FENDRR, CAT1886 and STCAT2 loci at the 16q23.1-q24.3 loss. Our data
confirm that the burden of SCNAs is predictive of biochemical recurrence, define nine indi-
vidual regions that are associated with relapse, and highlight the possible importance of ion
channel and G-protein coupled-receptor (GPCR) pathways in cancer development. We con-
cluded that a two-hit genetic model accounts for about one third of SCNA indicating that
mechanisms, such haploinsufficiency and epigenetic inactivation, account for the remaining
SCNA losses.
Author summary
Cancer is a genetic disease where changes in DNA cause alterations in the control of
cellular systems leading to unchecked growth. Copy number changes, including dupli-
cations, amplifications, and deletions, are a common type of DNA change observed in
cancer cells but it is not always clear which of the changes are important in driving can-
cer development. We have examined this class of genetic alteration in prostate cancer
by DNA sequencing the whole genome in 103 cancers. 64 recurrent copy number
changes were detected, of which 28 were new. For genetic losses our study comprehen-
sively assessed the role of a model called the “Knudson two-hit genetic model” where
alterations in both alleles of a gene is required to generate functional alterations. This
model was only supported a minor proportion of recurrent deletions (15/40). This
observation indicates that other mechanisms, such haploinsufficiency and epigenetic
inactivation, may account for the majority of deletions. Our studies highlight several
novel changes including those in non-coding lincRNA sequences, the identification
ZNF292 as a target gene for a recurrent deletion on chromosome 6, and the common
Knudson deletions at the NKX3.1 loci on chromosome 8.
Introduction
Somatic copy-number alterations (SCNAs) occur very frequently in human cancer and exactly
how these alterations contribute to cancer development is a subject of considerable interest.
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Mapping of SCNAs has identified recurrent sites of alterations in many cancer types, but only
a small proportion of such sites have unambiguously been assigned to specific cancer genes
[1].
Several models based on clonal evolution and selection may be invoked to explain recurrent
regions of chromosomal loss in the autosomes and sex chromosomes. In the classic model of
cancer development proposed by Knudson [2], mutations are required in each of the two cop-
ies of a single gene: the loss of an allele is considered as one mutation and the remaining allele
would be altered by loss (homozygous deletion), mutation or rearrangement. This is due to
strong positive selective pressure for alteration of both alleles. In principle, inactivation of the
remaining allele might also involve epigenetic inactivation through DNA methylation. Hap-
loinsufficiency is also an established mechanism of cancer development, where loss of only a
single allele is required for cancer development; expression of the normal allele is retained in
the cancer, albeit at a lower level. This model is supported in prostate cancer by transgenic
mouse studies for NKX3.1 and p27Kip1 [3,4].
Solimini et al. [5] have provided a model, where the collective contribution of many genes
may provide selective advantage to a cancer cell, possibly overlapping with the Knudson
model. De et al. and Fudenberg et al. have proposed a model where 3D chromatin organization
and spatial co-localization of DNA regions during replication may explain the generation of
copy number alterations [6,7]. Another explanation is that alterations are simply the hallmark
of an unstable genome and have no particular functional significance, for example reflecting
fragile genomic sites. Similar consideration can be given to regions of genetic gain and amplifi-
cation where overexpression of one or more genes is believed in many cases to drive cancer
development [8].
Prostate cancer is the second most common cancer in men worldwide and in 2012 an esti-
mated 307,000 men died from prostate cancer worldwide [9]. Several studies have investigated
SCNA in prostate cancer [10–12], and critically, it has been established that the burden of SCNA
is associated with subsequent biochemical recurrence (rising Prostate Specific Antigen, PSA, lev-
els after radical prostatectomy) and metastasis independent of initial PSA levels and Gleason
scores. Similar observations were reported in a recent study where a 100-loci (276 genes) copy
number signature was predictive of biochemical recurrence [13]. However, only a small propor-
tion of the gains and losses have been unambiguously assigned to specific driving genes.
The current study is the first to implement a targeted approach in prostate cancer where
Whole Genome DNA Sequencing (WGS) data is used to comprehensively examine mutation
data in relation to the presence of SCNAs. We used WGS data from each patient to screen
recurrent SCNA regions for potentially functional alterations not only in protein coding
genes, but also in genomic regions encoding lincRNAs, in control regions, and in other con-
served DNA sequences. Understanding mechanisms of SCNA generation and the identifica-
tion of target genes, linked to clinical outcomes, may assist in identifying novel biomarkers
and therapeutic targets.
Results
Genome wide copy number profiles
ASCAT 2.2 [14,15] was used to identify somatic copy number alterations (SCNAs; S2 Table;
types of alteration defined in S1 Table) in WGS data for malignant samples taken from 103
prostate cancer patients (S2 Table). In cases of patients with multiple tumor samples a single
profile was used. The relationship between samples within a patient and the tumour evolution
for the 13 patients where there were multiple tumour samples has been previously investigated
[16,17]. ETS gene status was inferred from WGS data (S3 Table).
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When compared to prostatectomy cases, metastatic cancers had higher proportions of tet-
raploid genomes as defined by ASCAT (53% vs 19%; Fisher’s exact test, p = 0.0042; S4 Table),
significantly larger numbers of SCNAs (mean 83 vs 21; Mann-Whitney U p = 2.17x10-08),
higher copy number burden (percentage of the genome altered) (mean 31.24% vs 7.694%;
Mann-Whitney U p = 1.30x10-08), and longer average SCNA size (Mann-Whitney U p =
4.37x10-04). Patients with more than 44 SCNAS (the mean number of SCNAs in patients that
had progressed within six months) had worse prognosis (Log-rank test p = 0.027, median fol-
low up of 16.5 month; Fig 1A and 1B) than patients with fewer SCNAs, consistent with other
publications [13,18,19] linking higher numbers of SCNAs to poorer outcome. Patients with
higher copy number burden had worse prognosis (Log-rank test p = 0.023; Fig 1C and 1D).
Classification of prostate cancer based on copy number profiles
Hierarchical clustering analysis was applied on overlapping SCNAs present in at least five
patients. A binary matrix was constructed on the basis of a patient having a region of amplifica-
tion or deletion (1) or not (0). Five major clusters were observed: C1-C5 (Fig 2; S5 Table). C5
and C4 were composed mainly of metastatic cases (6/13 and 5/7) while the remaining metastatic
cases were placed in C2 (3/39) and C3 (2/16). Patients in C1 had fewer SCNAs than those in
C2-C5 (mean 6.79 vs 40.32 SCNAs) and lower copy number burden (mean 1.64% vs 14.98%).
Prostatectomy/TURP patients in C1 had no significant difference in Gleason Scores (X2 test
p = 0.213; Fig 3A) or in their levels of PSA at diagnosis (Mann-Whitney U p = 0.929). Prostatec-
tomy patients in C1 had a significantly better prognosis (Log-rank test p = 0.028; Fig 3B).
Detecting regions of recurrent alteration
We defined a recurrent region of alteration as the minimal region of overlap that contains
supporting alterations from five or more patients (minimal MRA, Fig 4A). 40 regions of dele-
tion and 24 regions of gain were identified (S6 Table). To identify potential driver genes, we
Fig 1. Somatic copy number alterations in 103 patients. (A) Somatic copy number alterations in relapse free (n = 59) and progressed patients
(n = 10) after radical prostatectomy at six months and (B) association with time to biochemical recurrence (the two groups were defined relative to the
mean number of SCNAs in progressed patients (44 SCNAs) within the cohort). Progressed patients had significantly more SCNAs than relapse free
patients (a mean of 19 compared to 44; Mann-Whitney U p = 0.0133). (C) Copy number burden in relapse free and progressed patients after radical
prostatectomy at six months and (D) association with time to biochemical recurrence (the two groups were defined relative to the mean copy number
burden in progressed patients within the cohort). Progressed patients had lower copy number burden (mean of 7.359 compared to a mean of 11.710;
Mann-Whitney U p = 0.0166).
https://doi.org/10.1371/journal.pgen.1007001.g001
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screened sequencing data to determine whether each MRA contained point substitutions,
insertions and/or deletions within the coding region of genes (Table 1, S7 Table), in cancer-
related and conserved lincRNAs from MiTranscriptome [20] (S8 Table), in promoter regions
(S9 Table) and in DNA High-occupancy target (HOT) regions [21] (S10 Table). To reduce the
effect of outlier measurements in our data, when screening for mutations we used a larger
minimal common region of alteration, referred to as the extended MRA, which is defined by
removing the two alterations that were closest to the 5’ boundary of the minimal MRA and
similarly the two alterations closest to the 3’ boundary (S1 Fig, S6 Table). We also applied the
statistical method GISTIC [22] to define significant regions of gain and loss (15 gains and 19
losses, residual q< 0.05, S11 Table). 14 losses and one gain were common to our list of mini-
mal MRAs and 5 losses and 14 gains were only detected by GISTIC (S6 Table). 16 out of 34 sig-
nificant GISTIC regions (residual q< 0.05) were also detected in other prostate cancer studies
that applied GISTIC [23,24], only four of which were not detected by our approach.
Fig 2. Cluster dendogram and heatmap of somatic copy number alterations in 103 patients. Cluster dendogram and heatmap of amplifications (red)
and deletions (blue) representing the somatic copy number profile of the 103 patients calculated using unsupervised hierarchical clustering with Manhattan
distance and complete inter-cluster linkage. Samples with SNP6.0 data are indicated with an asterisk. Confidence intervals determined by multiscale
bootstrap resampling are displayed in S2 Fig.
https://doi.org/10.1371/journal.pgen.1007001.g002
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Known regions of genetic alteration
The most frequent MRAs were located at 8p21.3-p21.2 (60% loss), 6q15 (49%), 13q14.13
(46%) and 10q23.31 (39%), in agreement with previous studies [18,24–26] (Fig 5, S3 Fig).
8p21.3-p21.2 is an example of a loss where haploinsufficiency has been proposed as the pri-
mary mechanism. The minimal MRA contains 16 coding genes, including NKX3.1, a suggested
target gene for this region [24,25] (Fig 5B). The lincRNA KCCAT306 (MiTranscriptiome ID)
was the only sequence mutated more than once (S8 Table). NKX3.1was however, affected by a
homozygous deletion in three patients (S12 Table). 1.1MBp from the minimal MRA there is a
region affected by homozygous loss in five patients containing PPP2R2a, EBF2, BNIP3L,
PNMA2 and DPYSL2. BNIP3L, which counteracts the apoptotic inducer BNIP3, is another
proposed target [26].
By comparison, 10q23.31 provided an example where alterations in both alleles are
observed, consistent with the Knudson two-hit model [2], with PTEN as the target. A high pro-
portion of the deletions were homozygous losses (11/39, S12 Table, Fig 5C). In seven cases
when one allele was deleted, a mutation was found at the remaining PTEN allele (Table 1).
PTEN alterations were more common in metastatic disease than in the prostatectomy series
(93% vs 29%; Fisher’s exact test, p = 1.0x10-08). Consistent with previous studies [27,28], some-
times only the 5’ end of the PTEN gene was lost. 17p13.1 (35%) is another example of this class
(S2T Fig, Table 1) where TP53 was affected by mutation in nine patients who all had an associ-
ated SCNA and homozygous loss was seen in two patients.
MAP3K7, a proposed target for the 6q14.3-q15 deletion [25,26] is located 2.4Mbp away
from the extended MRA (Fig 5A). ZNF292was mutated on the remaining allele in one patient
and has been found to be rearranged in prostate cancer [29]. The lincRNAs KHCAT274 and
KHCAT370 (MiTranscriptiome IDs) in the extended MRA were mutated four times on the
allele that remained after deletion (Fig 5A, S8 Table). The known deletion at 17q21.31
[18,23,26] (Fig 5F) had a minimal MRA that contained UBTF, a known fusion partner of
ETV4 [30].
Fig 3. Cluster associations with clinical factors. (A) Clusters association with Gleason Score (prostatectomies and TURP samples only). (B)
Clusters association to risk of biochemical recurrence within C1 and C2-C5. At the time of writing the single prostatectomy case in C5 had a follow
up time of 23 months and had not progressed.
https://doi.org/10.1371/journal.pgen.1007001.g003
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Fig 4. Frequency plot representing regions of amplification (red) and deletion (blue). Across samples from (A) all 103 patients, (B) ETS-
positive cancers, and (C) ETS-negative cancers. SCNAs present in more than one patient were plotted. The green lines represent the cut-off (5
patients) for defining recurrently altered regions. Chromosome numbers are indicated in black. Genes potentially involved in prostate cancer
development in the minimal regions of alteration are annotated in black.
https://doi.org/10.1371/journal.pgen.1007001.g004
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RB1 and BRCA2 are two proposed candidates for the MRA at Chromosome 13q14.13 (Fig
5D) [18,25,26]. RB1 is located 1.3MBp from the minimal MRA and within the extended MRA.
In three patients, a region of homozygous loss spans RB1 (S12 Table). BRCA2was 9.5MBp out-
side the extended MRA.
Deletions containing only one gene in the minimal MRA, were detected at 3p13 containing
RYBP (33.01%, S2D Fig), 12p13.1 containing CDKN1B (27.18%, S2N Fig), and 14q24.1 con-
taining RAD51B (10.68%, Fig 5E) but none had mutations in the remaining allele (Table 1, S6
Table).
Gains at Chr8q exhibited a complex structure with three broad peaks (Fig 6A, S4 Fig). The
proposed target of 8q24.21, MYC, was located 48kb from the minimal MRA and was present
in the extended MRA. Thirteen mutations were found in total at PCAT1 and CCAT1 with
seven accompanying chromosome gain (S8 Table). The amplification at 7p11.2, present in
11.65% of patients, contained EGFR in the minimal MRA (Fig 6B). The extended MRA region
contained a total of seven mutations with the highest number in lincRNA CAT941. Amplifica-
tion of 14q13.3-q21.1 (Fig 6C) contained only FOXA1 and MIPOL1.
Novel regions of recurrent genetic alteration
24 additional novel recurrent regions of loss and gain were detected (S6 Table, S1 Appendix),
including regions of loss with more than 15% frequency at 4p15.2-p15.1 (15.53%), 6q27
(16.50%) and 18q12.3 (17.48%). Regions of gain with the highest frequencies were at 1q25.3
(8.74%), 5p15.31 (9.71%), and 10q21.1-q21.3 (8.74%). For two of these regions, 22q12.1-q12.2
Table 1. Genes that are recurrently altered by coding-changing mutations in regions of recurrent somatic copy number alteration defined by the
extended MRAs.
Gene Gene name Number of
mutations
Patients with a SCNA
and mutation
Patients with
SCNA (%)
Type of
SCNA
FOXA1 (14q21.1) Forkhead box protein A1 11 1 6 (5.83) Amp
TP53 (17p13.1) Tumor protein p53 9 9 37 (35.92) Del
PTEN (10q23.31) Phosphatase and tensin homolog 9 7 39 (37.86) Del
HMCN1 (1q25.3) Hemicentin-1 6 1 8 (7.77) Amp
KIF26B (1q44) Kinesin family member 26B 4 2 7 (6.80) Amp
KIAA1614 (1q25.3) Uncharacterized Protein KIAA1614 4 1 8 (7.77) Amp
TCF12 (15q21.3) Transcription factor 12 3 1 15 (14.56) Del
CACNA1E (1q25.3) Calcium channel, voltage-dependent, R type,
alpha 1E subunit
3 1 8 (7.77) Amp
PHYKPL/AGXT2L2
(5q35.3)
5-Phosphohydroxy-L-lysine phospho-lyase 3 0 8 (7.77) Amp
SCN4A (17q23.3) Sodium channel protein type 4 subunit alpha 3 0 4 (3.88) Amp
C17orf58 (17q24.2) Chromosome 17 open reading frame 58 3 0 4 (3.88) Amp
RYR2 (1q43) Ryanodine receptor 2 3 0 12 (11.65) Amp
ZFHX4 (8q21.11) Zinc finger homeobox 4 2 2 31 (30.10) Amp
TRPA1 (8q13.3) Transient receptor potential cation channel,
subfamily A, member 1
2 2 31 (30.10) Amp
NBN/NBS1 (8q21.3) Nibrin 2 2 32 (31.07) Amp
COL27A1 (9q32) Collagen, type XXVII, alpha 1 2 1 5 (4.85) Amp
AMBP (9q32) Alpha-1-microglobulin/Bikunin precursor 2 1 5 (4.85) Amp
UIMC1 (5q35.2) Ubiquitin interaction motif containing 1 2 1 6 (5.83) Amp
SLC26A2 (5q32) Solute carrier family 26 (anion exchanger),
member 2
2 1 8 (7.77) Amp
https://doi.org/10.1371/journal.pgen.1007001.t001
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Fig 5. Examples of minimal recurrent deletions. Deletions at (A) 6q14.3-q15, (B) 8p21.3-p21.2, (C)
10q23.31, (D) 13q14.13, (E) 14q24.1 and (F) 17q21.31. The genomic location of the MRA and linked genes
are displayed. For the loss at 8p a recurrent region of homozygous loss (8:25417422–26386565) close to the
MRA is indicated.
https://doi.org/10.1371/journal.pgen.1007001.g005
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and 17q22-q23.1, Fraser et al. found a very close recurrent region of copy number alteration
[24]. Within the extended MRA no more than a single mutation was observed. These novel
regions of recurrent genetic alteration require confirmation in other, larger series.
Novel targets in regions of genetic alteration
Apart from PTEN and TP53 the most frequently mutated genes in extended MRAs are FOXA1
(Fig 4C), HMCN1, KIF26B, and KIAA1614, indicating potential targets (Table 1). For KIF26B,
NBN, TRPA1 and ZFHX4 the alleles were commonly both amplified and mutated. Gains in NBN
are predictive of biochemical relapse in patients treated with radiotherapy [31]. Several lincRNAs
were identified as potential novel targets (S8 Table). KCCAT42, FENDRR,CAT1886 and STCAT2
provided a hotspot of mutations within the loss at 16q23.1-q24.3: 17/33 mutations occurred in
the remaining allele following loss. KCCAT91, CCAT1, CAT1886 and KCCAT199 were all found
frequently mutated (> = 7 patients with mutation) and found to be concurrent with the associ-
ated SCNA more that 50% of the time. Single mutations in the promoters of only two genes
(NKX2-6 and TPBGL) occurred concurrently with heterozygous loss (S9 Table). XOT.290 was
the only DNA High-occupancy target (HOT) region found to be mutated in more than two
patients (S10 Table).
The most frequently altered genes within regions of homozygous loss outside the MRAs
were PCDH17, SYNE1, ASXL2, DNAH9, KIF1A, LMO7 and LRP1B (S7 Table). Except for
ASXL2 and LMO7, all these genes are reported to be frequently methylated in prostate and/
or other cancers [32–37]. Deletion and mutations in ASXL2, a chromatin/histone modifier
gene that interacts with AR, are associated with castration resistant prostate cancer [38].
PCDH17 methylation is predictive of biochemical recurrence after radical prostatectomy
[39,40].
Conserved regions of DNA in regions of genetic alteration
Conserved regions of DNA were determined from multiple alignments of 45 vertebrate
genomes to the hg19 human genome (UCSC phastCons p-value> 0.95). Deletion MRAs were
significantly enriched for conserved regions (p = 0.0058; Wilcoxon signed rank test) while
gains were not (p = 0.53). Deletions at extended MRAs 12p13.1 (28 patients), 17p13.1 (37
patients) and 17q21 (20 patients) had the highest percentage of conserved sequence (>10%, S6
Table). Recurrent mutations were found in 20 conserved regions (S13 Table). Of potential
interest is the conserved region at 14:38061176–38061238 within the FOXA1 gene with five
mutations, which are exclusively found in patients without the SCNA. One of these, FOXA1
M253R, was observed at the forkhead domain, a site of common mutation clustering [23].
Established tumor suppressor genes PTEN and TP53 had recurrent mutations in conserved
coding regions (S13 Table). 100% (9/9) of the mutations detected in PTEN were found in a
conserved region. Two of these mutations, PTEN Y68H and PTEN R173C, are known to
inhibit the activity of the phosphatase catalytic domain of PTEN [41] and occur frequently in
gliomas and endometrial cancers [42]. In addition, KIF26B and HMCN1 also had recurrent
mutations in three or more patients in conserved coding regions. KIF26B is associated with
poor prognosis in breast and colorectal cancers [43,44].
Fig 6. Examples of gains. Gains within the (A) q arm in Chr8, (B) focal amplifications at 7p11.2, and (C) 14p11.2. Three spatially separated regions of gain
were present at 8q24.21. The chromosome gain events are represented with distinct colour blocks depending on the type of SCNA: gain (any gain in the
number of normal allele copies) and amplification LOH (loss of one allele with any gain of the remaining allele). The regions of SCNA are ordered by length:
top-smallest, bottom-largest. The genomic location of the MRAs and linked genes are additionally displayed.
https://doi.org/10.1371/journal.pgen.1007001.g006
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Deletions frequently occur in combination with inversions and other
chromosomal rearrangements
Analysis of WGS using the Brass algorithm identified breakpoints not associated with the copy
number change within or close to the extended MRA. Recurrent breakpoints affecting four or
more patients were identified in 153 genes (S14 Table). A common feature of many of these
genes is that a region of inversion affects them. For example, out of the fifty patients that have
the MRA deletion at 6q14.3-q15, in 14 patients there is a region of inversion found covering
15 genes including GJB7, HTR1E, SLC35A1, ZNF292which have been found to be affected by
breakpoints previously [29]. ZNF292was also found to have homozygous deletion in two
patients and a mutation in one patient. Taken together, ZNF292 therefore seems the likely tar-
get of this deletion. PCNXL2, TBCE, and THSD7B presented a chromosomal rearrangement in
the remaining allele in more than 40% of patients with a SCNA. THSD7B, a gene involved in
the TGFβ signaling pathway, has been previously found to be the target for mutations [45].
NCKAP5 is a gene in the large region of inversion at 2q21.3-q22.1 and has been observed to be
rearranged in prostate cancer by FISH [46]. Regions of inversions were also observed in GIS-
TIC detected deletions (S15 Table). For example, 15 patients have an inversion at the 2q22.1
deletion that covers SPOPL, NXPH2 and HNMT, of which at least four also had a deletion.
SPOPL is capable of associating with the putative transcriptional regulator of AR [47,48],
SPOP and has been previously found to be the target of recurrent mutations [23,29].
Clinical correlations
Clinical correlations were made using data from prostatectomy patients (S6 Table). No MRAs
were significantly associated with Gleason score (X2 test (FDR); p> 0.05) or PSA levels (Mann-
Whitney U (FDR) p> 0.05). Two deletions and seven gains were significantly associated with
time to biochemical recurrence (Log-rank test (FDR); p< 0.05, Fig 7). This includes a loss at
1q42.2-q42.3 which contains ARID4B, a chromatin-remodeling gene that interacts with RB1,
and reduced expression is associated with the development of breast and other cancers [49,50].
Five of these nine regions were validated as having a significant association with biochemical
recurrence in two other datasets, TCGA [23] and Taylor et al. [18], with a further two regions
validated in one dataset (Log-rank test (FDR); p< 0.05, S6 Table). Seven of the nine regions
with a significant clinical association were identified as novel recurrent regions of loss and gain.
Six of these were validated in at least one other dataset (S6 Table). GISTIC detected one of the
regions, 4p15.2-p15.1, exhibiting clinical significance.
ETS gene fusions and pathway enrichment analysis
49 patients had ETS positive (48%) and 54 patients (52%) had ETS negative cancers (Fig 4B
and 4C). Deletions at 3p13 (RYBP), 17q21.31, 20p13, 21q22.2, 21q22.3 and 22q13.31 and
amplifications at 2q24.3 and 16p13.3 were more commonly present in ETS-positive cancers
(Fisher’s exact test, p< 0.05, S6 Table). Deletions at 1q42.2-q42.3, 2q21.3-q22.1, 4q22.3, 5q21.1
(CHD1), 6q14.3-q15 and 13q14.13 and amplifications at 3q22.1-q21.3, 7p11.2 (EGFR), 8q11.1-
q11.21, 8q21.11-q22.1, 8q24.21, 9q33.1, 12q23.1 and 14q13.3-q21.1 (FOXA1) were more com-
monly present in ETS-negative cancers (Fisher’s exact test, p< 0.05). These observations are
in agreement with previous studies associating subtypes of ETS negative cancers with CHD1
(5q21.1) [23,51,52], FOXA1 (14q13.3-q21) [51], 2q21.3-q22.1 [23], 6q14.3-q15 [23,53], and
13q14.13 deletions [23] and ETS positive cancers with PTEN deletion [18,23,54] (Fisher’s
exact test, p = 0.08). Several new associations with ETS negative cancers were found, including
deletions at 1q42.2-q42.3 & 4q22.3, and amplifications at 3q22.1-q21.3, 7p11.2 (EGFR), & 8q
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(MYC). The deletion at 17q21.31 and the amplification at 16p13.3 were associated with ETS
positive cancers.
Reactome pathway enrichment analysis of ETS-positive and ETS-negative cancers was per-
formed (S5 Fig, S16 Table). Altered pathways and processes common to ETS-positive and
ETS-negative cancers were the cell cycle, cellular senescence, ion channels and WNT signaling.
Aberrations in the cell cycle are prognostic of outcome in prostate cancer patients [55,56].
The major pathways altered more prominently in ETS-positive cancers were the PI3K-AKT,
EGFR, TGF-beta Receptor Complex, PDGF and FGFR signaling pathways. ETS-negative can-
cers had more common alterations in the GPCR signaling pathway and DNA replication. An
additional analysis of genes altered by mutation in the significant regions of amplification,
deletion and homozygous loss showed enrichment of the DNA repair, PI3K/AKT and cell
cycle pathways with no difference between ETS-positive and ETS-negative cancers (S16
Table).
Discussion
Recently, driven by technological improvements and cost reductions, considerable attention
has been directed towards the whole genome analysis of cancer genomes. We employed this
technology to assess mechanisms of copy number gain and loss. Our study confirmed several
previous observations and yielded novel features of the human prostate cancer genome,
including highlighting the importance of lincRNAs in prostate cancer development [57–59].
Previously, lincRNAs PCAT1 and CCAT1 were identified as targets in the 8q24.21 gain [60,61]
and we confirmed this and demonstrated the presence of mutations in patients with gains.
PCAT1 and CCAT1 have been identified as prognostic markers in prostate and colorectal can-
cers acting as transcriptional regulators of the genes BRCA2 and MYC respectively [60,62]. We
also identified a hotspot of mutations at the KCCAT42, FENDRR, CAT1886 and STCAT2 loci
within the 16q23.1-q24.3 loss. Low FENDRR expression is associated with poor prognosis in
Fig 7. Minimal regions of deletion and amplification significantly associated with treatment failure. (A), 1q42.2-q42.3 deletion, (B) 4p15.2-p15.1
deletion, and (C) 1q21.3-q22 amplification. Kaplan-Meier freedom from biochemical recurrence are displayed. Log-rank test probabilities adjusted for
multiple testing by the Benjamini-Hochberg method are indicated. Ovals indicate the frequency of alteration.
https://doi.org/10.1371/journal.pgen.1007001.g007
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gastric cancer [63]. KCCAT91, CCAT1, CAT2185 and KCCAT199 were also identified as possi-
ble targets.
Our observations show that many well-characterised regions of recurrent loss are also the
site of clusters of breakpoints. The remaining allele of NKX3.1was affected by a breakpoint in
a high proportion of patients (8/62) suggesting that sometimes both alleles may be inactivated
(S14 Table). Supporting this view it has also been reported that 1% of prostate cancers contain
point mutations in the NKX3.1 allele [23], and rearrangement of this gene was also reported by
Baca et al. [29]. These observations are inconsistent with the view that inactivation of NKX3.1
always involves haploinsufficiency, although it is possible that both Knudson and haploinsuffi-
ciency, mechanisms are active. We found that the gene ZNF292was present in the minimal
MRA and was in a region of inversion or mutated in the remaining allele in 15 cases and had
homozygous loss in two cases providing strong support for ZNF292 as a classic two-hit target
at this locus. Rearrangements were also detected in the remaining allele at the CHD1, PTEN,
USP28 and TP53 loci. For PTEN deletion of one allele accompanied by loss of function of the
remaining allele caused by a chromosomal rearrangement was consistent with our previous
FISH studies of the PTEN allele [27].
We confirmed the finding of Taylor et al. [18,19] that the burden and number of SCNAs
are predictive of biochemical recurrence. We additionally identified nine regions that were sig-
nificantly associated with relapse. Pathway analysis of genes present in deleted regions had pre-
viously identified cell cycle (RB1), PI3K, WNT and RAS/RAF pathways [18,48]. We have
confirmed the importance of DNA repair pathways [23,48] and highlighted other processes
including ion channel and GPCR signalling pathways.
We also assessed whether our analysis using whole genome DNA sequencing data were
consistent with previously proposed mechanisms accounting for gains and losses. The PTEN
gene provides a classic example of a Knudson two hit model where both alterations involve
genetic alterations: deletion of one allele is accompanied by rearrangement or mutation in the
remaining allele. However, we could find few other examples of this model (15/40 MRAs)
when specifying that alterations must occur exclusively within the extended MRA (Table 2; S2
Appendix). This is confirmed with the regions detected by GISTIC (13/31 regions; S17 Table).
One possibility is that regions of loss may be accompanied on the opposite alleles by alterations
in mini-drivers genes [64] thus making a small but selectable contribution to cancer develop-
ment. Recurrent mutations within the regions of copy number change were predominantly
(81%) in cases that had not lost or gained an allele. Such alterations (for example FOXA1,
KIF26B and the lincRNAs CAT1800 at 16p13.3, KHCAT81 at 16p13.12-p13.11 and BRCAT9
and BRCAT3 at 11q14.3) are possible haploinsufficiency targets (S7 Table).
From these analyses, we conclude that a simple genetic Knudson model does not account
for the majority of deletions in prostate cancer. It is possible that genes in the remaining allele
may be inactivated by methylation or that haploinsufficiency may account for regions of gene
loss.
The criterion for membership of this group was that there had to be at least four muta-
tions (excluding synonymous changes), breakpoints within the gene or inversions affecting
the gene in the remaining allele of a gene in the extended MRA. Multiple genes are dis-
played when an inversion affects multiple genes and there is no additional evidence of
which one is the target. USP28 is located very close to the extended MRA at 12q23.2 and
probably represents another example of the Knudson two hit model. KCCAT42, FENDRR,
CAT1886 and STCAT2 are a cluster of lincRNAs. A version of this table for GISTIC regions
can be found in S17 Table.
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Table 2. Summary table of recurrent regions of deletion that follow the Knudson hit model.
Minimal Region
of Alteration
Band
Candidate Genes/
Region
Chromosomal
Location
Number of
Patients with
Deletion
Homozygous
Deletion
Number of Patients
affected by Deletion
and a Point Mutation/
Indel on the opposite
allele
Number of Patients
affected by Deletion and
a Breakpoint/Inversion
on the opposite allele
1q31.1 AK5, GIPC2, LPHN2, &
TTLL7
1:77747736–
84464833
19 0 0 5
1q42.2-q42.3 PCNXL2 & TBCE 1:233119181–
235612283
14 0 0 6
2q21.3-q22.1 12 genes inc. CCNT2,
ZRANB3, CXCR4,
DARS, NCKAP5
2:133429374–
136875735
16 0 0 4
2q21.3-q22.1 THSD7B 2:137523115–
138435287
14 0 0 6
3p13 RYBP 3:72420976–
72496069
34 0 0 5
3p13 SHQ1 3:72798428–
72911065
33 0 0 4
5q21.1 CHD1 5:98190908–
98262240
29 6 0 8
5q21.1 KCCAT91 5:98150767–
100530128
32 4 5 6
5q21.1 ST8SIA4 5:100142639–
100238970
28 0 0 7
5q31.1-q13.2 MAP1B, MRPS27,
ZNF366
5:71403061–
71803554
22 0 0 4
6q14.3-q15 KHCAT370.2 6:87851165–
88089974
50 1 3 14
6q14.3-q15 ZNF292 6:87862551–
87973914
50 2 1 14
8p21.3-p21.2 NKX3.1 8:23536206–
23540440
62 3 0 8
8p21.3-p21.2 PEBP4, RHOBTB2,
TNFRSF10A,
TNFRSF10B,
TNFRSF10C,
TNFRSF10D
8:22570769–
23082639
62 0 0 9
11q23.2 USP28 11:113668596–
113746292
14 0 5 5
11q23.2 CADM1 & HTR3A 11:113845603–
115375675
15 0 0 4
12p13.1 DUSP16 & LOH12CR1 12:12510013–
12715317
27 0 0 4
12q24.33 TMEM132D 12:129556270–
130388211
14 0 0 4
13q14.13 RB1 13:48877887–
49056122
46 3 1 0
13q14.13 19 genes inc. GTF2F2,
HTR2A
13:45007655–
47471169
47 0 0 8
16q23.1-q24.3 KCCAT42, CAT1886.1,
FENDRR, STCAT2
16:78475408–
90287535
42 0 17 0
17p13.1 TP53 17:7565097–
7590856
37 2 9 5
22q13.31 CELSR1, FLJ27365,
PPARA, TRMU
22:46449749–
46933067
14 0 0 4
https://doi.org/10.1371/journal.pgen.1007001.t002
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Methods
Sample cohort
141 malignant samples from 105 patients with prostate cancer within the Cancer Research UK
ICGC Prostate Cancer Project were included in this study: 88 cancers collected after radical
prostatectomy, including 10 tumor and three blood samples from three men with complex or
multifocal disease; five cancers from men diagnosed with prostate cancer in Shanghai; two
cancers collected from transurethral resection of the prostate (TURP); 8 lymph node meta-
static samples from non-androgen deprived patients; and 36 malignant samples from 7 men
with metastatic disease belonging to the PELICAN rapid autopsy program [17]. Samples were
collected subject to ICGC standards of ethical consent. Ethical approval for this work was
obtained from the respective local ethics committees (NHS South West London REC [10/
H0806/113]; NHS East Midlands–Derby REC [01/4/061]; NHS East of England—Cambridge
REC [03/018]; John Hopkins IRB [NA_00003925]; Changhai Hospital Ethics committee; Joint
Chinese University of Hong Kong-New Territories East Cluster Clinical Research Ethics Com-
mittee [CRE-2011.373]) and from The Trent Multicentre Research Ethics Committee [MREC/
01/4/061]. Explicit informed written consent was obtained from all participants to the use and
storage of their genetic material and tissue samples in research, including whole genome
sequencing. Explicit written consent was also obtained for any data derived from these sam-
ples, along with coded clinical/health data, to be placed on an international database (ICGC)
and made available to ICGC members and other international researchers under open or con-
trolled access. Prostatectomy samples were collected as described previously [65]. Blood sam-
ples were used as normal controls except for PELICAN samples where normal tissue was used.
DNA preparation and DNA sequencing
DNA from whole blood samples and frozen tissue was extracted and quantified using a ds-
DNA assay (UK-Quant-iT PicoGreen dsDNA Assay Kit for DNA) following manufacturer’s
instructions with a Fluorescence Microplate Reader (Biotek SynergyHT, Biotek). Acceptable
DNA had a concentration of at least 50ng/μl in TE (10mM Tris/1mM EDTA), with an OD
260/280 between 1.8–2.0. For aCGH at least 10μl equivalent to 500ng were used for hybridisa-
tion to the Affymetrix SNP6.0 array. WGS was performed at Illumina, Inc. (Illumina Sequenc-
ing Facility, San Diego, CA USA) or the BGI (Beijing Genome Institute, Hong Kong) as
described previously to a target depth of 50X for the tumor samples and 30X for matched con-
trols [66]. The Burrows-Wheeler Aligner (BWA) was used to align the sequencing data to the
GRCh37 human genome [66].
Generation of segmented copy number profiles
Pseudo-SNP6.0 profiles were created for each tumor and matched control from whole genome
sequencing data. In a small number of cases data was obtained directly from Affymetrix
SNP6.0 arrays (S18 Table) and rescaled and transformed using PennCNV [67]. ASCAT 2.2
was then used to generate segmented copy number profiles and estimate the purity and ploidy
of the sample using a penalty of 50 and gamma value of 1 [14,15]. Note that given the target
sequencing coverage of 50x/30x, there may be stochastic regions of low coverage where true
segments are not detected. Two prostatectomy samples with low estimated tumor content
were removed from further analysis. Data from the matched control is used to reduce false
positives. A conservative filtering strategy was used to ensure the best quality of segments are
obtained and give us the greatest confidence in the minimal regions of alteration that we call.
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8876 segments were removed, of which 6692 were removed based on the following filtering
criteria:
• Segment was within centromeric or telomeric regions (extended by 1,000,000 bp).
• Segment was within low mapability regions as defined by ENCODE (extended by 1,000,000
bp).
• Segment copy number of major allele (nMajor) >25 and copy number of major allele
(nMinor) = = 0, or nMajor> = 10 and length was less than 500,000bp.
• Segment where the minor allele copy number is larger than the major allele copy number.
• Segment had less than 50 supporting SNPs and length was less than 100,000bp
The remaining 2184 segments were filtered out upon visual inspection in a blind fashion.
Visual inspection included checking that the change in copy number was in agreement with
the overall ploidy of the sample, that there was a change in BAF and total copy number, and
that the SNPs within the segment didn’t have high variance. In the majority of cases segments
were removed because ASCAT did not get the appropriate fit and there was no obvious copy
number change. In this and other ICGC projects we have generally found that visual inspec-
tion of any class of alteration is an excellent method for filtering out incorrect calls made by
the algorithms. Similar results were obtained from SNP6.0 and pseudo-SNP6.0 profiles (S6
Fig). We also applied the statistical method GISTIC v2.0.16 [22] to define significant regions of
gain and loss, using the default parameters. Note that all pre-filtered segments were used when
the GISTIC algorithm was applied.
Conversion of sequencing data to a pseudo-SNP6.0 profile
The number of reads for each nucleotide base at each probe position on the Affymetrix
SNP6.0 na32 hg19 annotation was extracted from sequence using deepSNV [68]. The loga-
rithm of the ratio (LogR) between allele A and B and the B allele frequency (BAF) were calcu-
lated as follows:
LogRi ¼ log2ðAi þ BiÞ
BAF ¼
Bi
ðAi þ BiÞ
where Ai is the read count for allele A for probe i and Bi is the read count for allele B. For CN
probes:
LogRi ¼ log2ðNiÞ
where Ni is the total number of reads at the position of probe i. The LogR values were normal-
ised:
LogRi ¼ LogRi   medianðLogRÞ
SNP probes with no reads at A and B alleles or with a BAF of 1 or 0 were removed. Using the
SNP6 array probe positions for WGS data with ASCAT is a common approach, used success-
fully in the ICGC pancancer analysis of whole genomes project (https://dcc.icgc.org/pcawg)
[69]. A wrapper program for ease of use is available [70].
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Calculation of the minimal regions of alteration (MRA)
Data from patients with multiple tumor samples is collapsed into one copy number profile per
patient using all detected regions. Overlapping regions of SCNAs were identified across all
patients by applying the GenomicRanges coverage function [71]; amplifications and deletions
were analysed independently. The minimal MRA is defined by identifying the region most fre-
quently altered in each peak region of overlap between five or more patients. This is an arbi-
trary threshold, but simplifying segment calling to a random process and assuming that a copy
number will be called in a region 1% of the time by chance (which we would consider high),
then given five patients, it is significantly likely that the true number of segments is greater
than 1% (p = 0.0039; Exact binomial test). The extended MRA expands the minimal MRA by
taking the start position of the overlapping segment with the third largest start position and
the end position of the segment with the third smallest end position (S1 Fig).
Mutational screen
Substitutions, insertions and deletions were detected using the Cancer Genome Project Well-
come Trust Sanger Institute pipeline. An updated version of this pipeline is available as a Docker
image (Alignment: https://dockstore.org/containers/quay.io/wtsicgp/dockstore-cgpmap; Vari-
ant-calling: https://dockstore.org/containers/quay.io/wtsicgp/dockstore-cgpwgs). The Burrows-
Wheeler Aligner’s Smith-Waterman Alignment (BWA-SW) v0.5.9-r16+rugo was used to align
the sequencing data from each lane to the GRCh37 reference human genome using parameters
-l 32 -t 6 [72]. Lanes that pass quality control are merged into a single well-annotated sample
BAM file with PCR duplicate reads removed. Substitutions were detected using CaVEMan v1.3,
an in-house bespoke algorithm developed at the Sanger Institute (http://cancerit.github.io/
CaVEMan/), with a cut-off ‘somatic’ probability of 95%. CaVEMan utilises a Bayesian expecta-
tion maximization (EM) algorithm: Given the reference base, copy number status and fraction
of aberrant tumor cells present in each cancer sample, CaVEMan generates a probability score
for potential genotypes at each genomic position. Further post-processing filters were applied to
eliminate false positive calls arising from genomic features that generate mapping errors and sys-
tematic sequencing artifacts. In comparisons with other mutation callers it has been found to be
amongst the top performers in terms of sensitivity and specificity [73]. Only substitutions that
were a missense, nonsense, start-lost, or occurred in a non-coding transcript were considered.
Insertions and deletions were called using a lightly modified version of pindel v4.2 [74] (http://
cancerit.github.io/cgpPindel/). Only indels that were inframe, frameshift, or occurred in a non-
coding transcript were considered. Structural variants were detected using Brass (Breakpoints
via assembly) v1.0.3, an in-house bespoke algorithm developed at the Sanger Institute (https://
github.com/cancerit/BRASS). In brief, the first step is to combine discordant read pairs into
potential regions where a breakpoint might occur. Next, reads around each potential region,
including half-unmapped reads, are gathered and a local de novo assembly using Velvet is per-
formed [75]. By analysing the De Bruijn graph pattern the breakpoint can be identified down to
base pair resolution. Any breakpoints where an exact location could not be determined were
removed. A positive ETS status was assigned if a breakpoint between ERG, ETV1 or ETV4 and
previously reported partner DNA sequences [76] were detected. Genes in each MRA were iden-
tified using good quality transcripts annotated in the EnsEMBL Genome Reference Consortium
Human Build 37.p13 (GRCh37.p13).
The mutational screen of homozygous loss was performed in any region that had a homozy-
gous loss in at least one sample. For mutations that occur within promoters, EPDNew human
version 003 [77] was used to define promoter regions. Conserved regions of DNA were deter-
mined from UCSC phastCons scores for multiple alignments of 45 vertebrate genomes to the
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hg19 human genome using a threshold p-value of 0.95. We used 7,942 long noncoding RNAs
(lincRNAs) from the MiTranscriptome project that were detected in 7,256 RNA sequencing
libraries from tumors, normal tissues and cell lines and defined as being either cancer-associ-
ated or containing conserved regions [20].
Statistical tests and survival analyses
All statistical tests were performed in R [78]. For comparisons between groups the non-
parametric Mann-Whitney U test was used for continuous variables and the X2 test with
Yates’ continuity correction or Fisher’s exact test was used for categorical variables. For all
statistical tests used there is the assumption of independence between data and we have
ensured this is the case by only using one copy number profile per patient in all compari-
sons. The sample used for the copy number profile was chosen at random (see S2 Table for
selection). In all cases where the X2 test was applied no cells in the contingency table had an
expected value less than 5.
Clinical associations were determined using standard statistical tests with Benjamin-Hoch-
berg multiple testing correction applied. The log-rank test was used to perform survival analy-
ses with biochemical recurrence after prostatectomy as the end point for survival analyses.
Reasonable assumptions were made i.e. censoring is unrelated to progress, survival probabili-
ties are the same for subjects recruited early and late in the study, and events happen at the
times specified. 84 out of 86 prostatectomy patients were used; two patients had incomplete
clinical data (0040 and 0052). For the patients where data was available from multiple samples,
the patient was classified as having the minimal region of alteration if it occurred in any of the
samples.
Pathway analysis
The enrichment analysis was performed by exploring the Reactome canonical pathways using
the Reactome plugin in Cytoscape [79] using the genes contained within the extended MRAs.
Integration of Reactome and Kyoto Encyclopaedia of Genes and Genomes (KEGG) canonical
pathways pathway analysis [80] was used to construct a map of the major pathways altered in
prostate cancer within our cohort.
Identifying genes affected by rearrangements
Rearrangement breakpoints within the extended MRA and within the significant GISTIC
regions (q-value < = 0.05) were selected and used to define associated gene allele-specific
events. Deletions that had common regions detected by ASCAT2.2 and Brass or by ASC
AT2.2 only were included in the analysis. A gene was defined as being affected by a rear-
rangement, and hence a bi-allelic event, if an insertion, inversion or intra-chromosomal
breakpoint occurred within the gene region or the gene occurred within an inversion. If
a gene was inverted twice and the breakpoints of the rearrangement were outside the gene
coordinates it was assumed the gene was still functional; these even inversions were re-
moved from the analysis.
Data access
Sequencing data has been deposited at the European Genome-phenome Archive
(EGAS00001000262, S1 Table).
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Supporting information
S1 Fig. Diagrammatic explanation on minimal and extended MRA.
(PDF)
S2 Fig. Hierarchical clustering of 103 prostate cancer samples with multiscale bootstrap
resampling. The data are binary values corresponding to the presence/absence (1/0) of regions
of copy number gain and loss in each of the tumour samples. p-values were calculated via hier-
archical cluster analysis with multiscale bootstrap resampling of 1000 using Ward’s method
and the Manhattan distance. The analysis was performed using the pvclust package in R. Val-
ues at branches are AU (Approximately Unbiased) p-values (left, red), and BP (Bootstrap
Probability) values (right, green). Clusters significantly supported by the data (AU 95) are
indicated by the red rectangles.
(PDF)
S3 Fig. Copy number alteration segments detected by ASCAT that overlap with deletion
MRAs. Each deletion is represented as a distinct colour as shown in the key. Deletions are as
follows: neutral LOH (loss of one allele with duplication of the remaining allele); hemizygous
deletion LOH (loss of one allele); homozygous loss (loss of the two alleles); and other loss (loss
of one allele copy following whole genome duplication). Cases for which more than one sam-
ple was available are all indicated, however contribution to the frequency of the SCNA was
defined on a per patient basis. The regions of SCNA are ordered by length: top-smallest, bot-
tom-largest. Each block has been labelled with sample ID. (a) chr1 p31.1, (b) chr1 q42.2-q42.3,
(c) chr2 q21.3-q22.1, (d) chr3 p13, (e) chr4 p15.2-p15.1, (f) chr4 q22.3, (g) chr4 q27-q28.1, (h)
chr4 q34.3, (i) chr5 q13.1-q13.2, (j) chr7 q31.32-q31.33, (k) chr9 p22.3, (l) chr11 p13, (m)
chr11 q23.2, (n) chr12 p13.1, (o) chr12 q24.33, (p) chr14 q24.1, (q) chr14 q32.13, (r) chr15
q21.3, (s) chr16 q23.1-q24.3, (t) chr17 p13.1, (u) chr18 p11.32-p11.31, (v) chr18 q12.3, (w)
chr18 q23-q22.3, (x) chr19 p12, (y) chr19 q13.31, (z) chr20 p13, (a2) chr20 p12.1, (b2) chr20
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(PDF)
S4 Fig. Copy number alteration segments detected by ASCAT that overlap with amplifica-
tion MRAs. The chromosome gain events are represented with distinct colour blocks depending
on the type of SCNA: gain (any gain in the number of normal allele copies) and amplification
LOH (loss of one allele with any gain of the remaining allele). The regions of SCNA are ordered
by length: top-smallest, bottom-largest. Each block has been labelled with sample ID. Cases for
which more than one sample was available are all indicated, however contribution to the fre-
quency of the SCNA was defined on a per patient basis. (a) chr1 q21.3-q22, (b) chr1 q25.3, (c)
chr1 q43-q44, (d) chr2 q24.3, (e) chr5 p15.31, (f) chr5 q33.3-q35.2, (g) chr9 q33.1, (h) chr10
q21.1-q21.3, (i) chr11 q13.4-q13.5, (j) chr11 q14.3, (k) chr12 q23.1, (l) chr13 q11-q12.11, (m)
chr13 q33.3, (n) chr13 q33.3-q34, (o) chr14 q13.3-q21.1, (p) chr16 p13.3, (q) chr16 p13.3, (r)
chr16 p13.12-p13.11, (s) chr17 q22-q23.1, (t) Chr8q11.1-q11.21, (u) Chr7p11.2, (v)
Chr8q21.1-q12.1, (w) Chr8q24.21, (x) Chr3q22.1-q21.3.
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S5 Fig. Commonly altered pathways in ETS positive and negative cancers. Blue and red
blocks indicate genes contained in regions of deletion and amplification respectively. Grey
blocks indicate genes with no alteration that were required for representation of the pathway.
Purple and blue squares indicate the percentage of samples with a copy number alteration in
Appraising the relevance of copy number loss and gain in prostate
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1007001 September 25, 2017 20 / 28
that gene in ETS negative and positive samples.
(PDF)
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Right side: Prostatectomy samples where there was at least six months follow up (n = 69) classi-
fied by whether there was rapid biochemical recurrence within six months of prostatectomy
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